MiRNAs as potential biomarkers for the diagnosis of fibromyalgia

Abstract

Fibromyalgia is a worldwide, non-inflammatory rheumatological syndrome considered by extensive musculoskeletal pain, which is the furthermost public sign. Fibromyalgia as well is associated with a diversity of additional multipart symptoms, including depression, fatigue, neuropathic pain, and irritable bowel syndrome, that often intersect with those of further diseases. Due to the inadequate understanding of the pathogenesis of Fibromyalgia, in addition to the lack of exact biomarkers and laboratory tests, the diagnosis and treatment of this disorder keep on challenging.In this review, we sightsee the probable efficacy of microRNAs as diagnostic biomarkers for Fibromyalgia. Recently, miR-145-5p and miR-451a have been proposed to be dysregulated in entities with Fibromyalgia. At the time miR-145-5p is involved in the regulation of pain perception and the modulation of inflammatory and neuropathic pain pathways; conversely, miR-451a has been concerned with the pathogenesis of depression, frequently comorbid conditions in Fibromyalgia patients. We emphasize these two microRNAs, miR-145-5p and miR-451a, and inspect their mechanisms and pathways in the framework of Fibromyalgia. By inspecting the underlying mechanisms through which these microRNAs contribute to the multifaceted symptomatology of Fibromyalgia, we goal to clarify their probable diagnostic use as biomarkers.